Searchable abstracts of presentations at key conferences in endocrinology

ea0098p11 | Population Science | NANETS2023

Sex differences during hospital stay among patients with neuroendocrine neoplasms

Ying Tan Wan , Cramer Laura D. , Vijayvergia Namrata , Lustberg Maryam , Kunz Pamela L.

Background: On the basis of prior large epidemiologic and retrospective studies on treatment-related side effects, it appears that there are sex-based differences in the epidemiology of NENs and treatment-related side effects. The purpose of this study was to examine sex differences in incidence, diagnoses present during hospital stay, and mortality among patients with NENs.Methods: The NIS database was used to define an unweighted sample of patients wit...

ea0098b25 | Basic Science | NANETS2023

A STING Operation in neuroendocrine neoplasms

Eagal Erika , Lou Emil , Gandhi Nishant , Elliott Andrew , Sukrithan Vineeth , Vijayvergia Namrata , Puri Sonam , Chauhan Aman , Hadfield Matthew , Florou Vaia , Affolter Kajsa , Vanderwalde Ari , Soares Heloisa P.

Background: Significant advances have been made in the treatment of gastrointestinal (GI-) and pancreatic (P-) NENs. However, the use of immunotherapy is still limited, with most tumors considered immune “cold”. The cGAS-STING signaling pathway has emerged as a critical mediator of inflammation and immune-mediated responses, with pathway agonists under development for enhancing immunotherapy. In this study, we evaluated associations between cGAS-STING pathway activit...

ea0098c30 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Novel alternate (Alt) response criteria for early outcome prediction in pancreatic (P) neuroendocrine tumors (NETs): utilizing banked imaging and radiomics

Lareef Ishara , Vijayvergia Namrata , Handorf Elizabeth , Kunz Pamela L. , Alkim Emil , Burke Lauren M. , Catalano Paul , Graham Noah , Levin Laura , Li Weier , Meeker Caitlin , Rubin Daniel , Sridharan Anush , O'Dwyer Peter J. , Wong Terence Z. , Anaokar Jordan

Background: Evaluating treatment (Tx) Response in NETs using CT/MRI scans can be difficult. Previous studies, including the E2211, have shown improved progression-free survival (PFS) but no significant difference in Rp as measured by RECIST 1.1 (R1.1) criteria. Therefore, it is difficult to determine Tx effectiveness with short-term imaging, further complicated by differences in imaging protocols and inter-reader variability. Incorporating tumor density, using smaller threshol...